Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Merger or Acquisition (October 2021)
11 slides from Bionano Genomics's merger presentation, Oct 12, 2021
Slide 1: Creating the Leading Variant Analysis Platform in Genomics
+ Erik Holmlin, PhD, CEO of Bionano GenomicsOctober 12, 2021 Creating the Leading Variant Analysis Platform in Genomics
Slide 2: Legal Disclaimer
Legal DisclaimerThis presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimate
Slide 3: Next Wave of Big Biology Driven by Structural Variation and Integrated Genome Analysis
NGS Microarray Structural Variation Analysis Molecular Diagnostics & Personalized Medicine Targeted Therapies Immuno Oncology CRISPR Gene Editing Consumer Genomics We Believe the Next Wave of Big Biology and Value Creation in Genomics Will Be Driven by Structural Variation and Integrated Genome Anal
Slide 4: Acquisition Expected to Accelerate and Broaden Bionano's Market Leadership
Acquisition Expected to Accelerate and Broaden Bionano’s Market Leadership in Cytogenomics and Comprehensive Genome Analysis Our vision is to make OGM ubiquitous, this vision requires exceptional softwareDelivering seamless integration with as many data types as possible, OGM can be used more broadl
Slide 5: Overview of BioDiscovery
Overview of BioDiscovery Headquartered in El Segundo, CAFounded by Dr. Soheil Shams, CEO2020: Revenue of $3.6M and profitable Software customers spanning the globeBest-in-class software for CNVsEnables Bionano to achieve expanded reach
Slide 6: Overview of BioDiscovery's NxClinical and Nexus CN Products
Overview of BioDiscovery’s NxClinical and Nexus CN Products BioDiscovery offers NxClinical and Nexus CN software solutions – the only platform agnostic data interpretation and reporting software that integrates NGS and microarray data to provide visualization of SNVs, CNVs and AOH across the genome
Slide 7: Software is THE Critical Interface
Software is THE Critical Interface - We Believe That Without Powerful and Seamless Software Users Cannot Get the Answers They Seek Acquisition enables Bionano to develop the most comprehensive variant analysis platform in genomics Software is how customers see, feel and comprehend OGM and is critica
Slide 8: Integration Plan & Operational Structure
Integration Plan & Operational Structure Dr. Soheil Shams becomes Chief Informatics Officer (CIO) of BionanoLocation in El Segundo, CA, preserved as Bionano software hubCIO integrated into Bionano software/informatics programsDrive integration of SV analysis pipelines into NxClinical software Stream
Slide 9: Planned Evolution of NxClinical Featuring OGM Data
Planned Evolution of NxClinical Featuring OGM Data:
Slide 10: Summary Terms
Summary Terms Bionano’s transaction consideration will be up to $100 million, consisting of a combination of cash and equity. A portion of the equity is subject to vesting based on continued service of key employees and a portion of the cash is contingent on achieving full integration of OGM data in
Slide 11: Transforming the Way the World Sees the Genome
Erik Holmlin, PhD, CEO of Bionano GenomicsOctober 12, 2021 + Transforming the Way the World Sees the Genome
Bionano Genomics — Merger or Acquisition (October 2021) on 6ix